Fractional Flow Reserve Computed Tomography

The Cardiovascular Phenomics Core (CPC) was a partner in the NXT Trial that led to Food and Drug Administration approval of HeartFlow fractional flow reserve computed tomography (FFR-CT) analysis – the first of its kind.

The CPC provided both FFR and quantitative coronary analysis (QCA) for the trial.

We played a key role in the first in U.S. clinical implementation of FFR-CT technology, which took place at University Hospitals Cleveland Medical Center in Cleveland, Ohio.